BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, while relapse and refractory ALL remains a leading cause of death in children. However, paired ALL samples of initial diagnosis and relapse subjected to next-generation sequencing (NGS) could construct clonal lineage changes, and help to explore the key issues in the evolutionary process of tumor clones. Therefore, we aim to analyze gene alterations during the initial diagnosis and relapse of ALL patients and to explore the underlying mechanism. METHODS: Targeted exome sequencing technology was used to detect molecular characteristic of initial diagnosis and relapse of ALL in 12 pediatric patients. Clinical features, treatment response, prognostic factors and genetic features were analyzed. RESULTS: In our 12 paired samples, 75% of pre-B-cell acute lymphoblastic leukemia (B-ALL) patients had alterations in the Ras pathway (NRAS, KRAS, NF1, and EPOR), and Ras mutation are very common in patients with ALL relapse. TP53 mutations mainly existed in the primary clones and occurred at the initial diagnosis and relapse of ALL. Relapse-associated genes such as NT5C2 and CREBBP were observed in patients with ALL relapse; however, all patients included in this study had gene abnormalities in the Ras pathway, and NT5C2 and CREBBP genes may collaboratively promote ALL relapse. CONCLUSIONS: Among the 12 ALL patients, Ras pathway mutations are common in ALL relapse and may be associated with other recurrence-related genes alterations. The study with paired samples could improve the understanding of ALL relapse. 2020 Translational Pediatrics. All rights reserved.
BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children, while relapse and refractory ALL remains a leading cause of death in children. However, paired ALL samples of initial diagnosis and relapse subjected to next-generation sequencing (NGS) could construct clonal lineage changes, and help to explore the key issues in the evolutionary process of tumor clones. Therefore, we aim to analyze gene alterations during the initial diagnosis and relapse of ALL patients and to explore the underlying mechanism. METHODS: Targeted exome sequencing technology was used to detect molecular characteristic of initial diagnosis and relapse of ALL in 12 pediatric patients. Clinical features, treatment response, prognostic factors and genetic features were analyzed. RESULTS: In our 12 paired samples, 75% of pre-B-cell acute lymphoblastic leukemia (B-ALL) patients had alterations in the Ras pathway (NRAS, KRAS, NF1, and EPOR), and Ras mutation are very common in patients with ALL relapse. TP53 mutations mainly existed in the primary clones and occurred at the initial diagnosis and relapse of ALL. Relapse-associated genes such as NT5C2 and CREBBP were observed in patients with ALL relapse; however, all patients included in this study had gene abnormalities in the Ras pathway, and NT5C2 and CREBBP genes may collaboratively promote ALL relapse. CONCLUSIONS: Among the 12 ALL patients, Ras pathway mutations are common in ALL relapse and may be associated with other recurrence-related genes alterations. The study with paired samples could improve the understanding of ALL relapse. 2020 Translational Pediatrics. All rights reserved.
Authors: Charles G Mullighan; Jinghui Zhang; Lawryn H Kasper; Stephanie Lerach; Debbie Payne-Turner; Letha A Phillips; Sue L Heatley; Linda Holmfeldt; J Racquel Collins-Underwood; Jing Ma; Kenneth H Buetow; Ching-Hon Pui; Sharyn D Baker; Paul K Brindle; James R Downing Journal: Nature Date: 2011-03-10 Impact factor: 49.962
Authors: Linda Holmfeldt; Lei Wei; Ernesto Diaz-Flores; Michael Walsh; Jinghui Zhang; Li Ding; Debbie Payne-Turner; Michelle Churchman; Anna Andersson; Shann-Ching Chen; Kelly McCastlain; Jared Becksfort; Jing Ma; Gang Wu; Samir N Patel; Susan L Heatley; Letha A Phillips; Guangchun Song; John Easton; Matthew Parker; Xiang Chen; Michael Rusch; Kristy Boggs; Bhavin Vadodaria; Erin Hedlund; Christina Drenberg; Sharyn Baker; Deqing Pei; Cheng Cheng; Robert Huether; Charles Lu; Robert S Fulton; Lucinda L Fulton; Yashodhan Tabib; David J Dooling; Kerri Ochoa; Mark Minden; Ian D Lewis; L Bik To; Paula Marlton; Andrew W Roberts; Gordana Raca; Wendy Stock; Geoffrey Neale; Hans G Drexler; Ross A Dickins; David W Ellison; Sheila A Shurtleff; Ching-Hon Pui; Raul C Ribeiro; Meenakshi Devidas; Andrew J Carroll; Nyla A Heerema; Brent Wood; Michael J Borowitz; Julie M Gastier-Foster; Susana C Raimondi; Elaine R Mardis; Richard K Wilson; James R Downing; Stephen P Hunger; Mignon L Loh; Charles G Mullighan Journal: Nat Genet Date: 2013-01-20 Impact factor: 38.330
Authors: Xiaotu Ma; Michael Edmonson; Donald Yergeau; Donna M Muzny; Oliver A Hampton; Michael Rusch; Guangchun Song; John Easton; Richard C Harvey; David A Wheeler; Jing Ma; HarshaVardhan Doddapaneni; Bhavin Vadodaria; Gang Wu; Panduka Nagahawatte; William L Carroll; I-Ming Chen; Julie M Gastier-Foster; Mary V Relling; Malcolm A Smith; Meenakshi Devidas; Jaime M Guidry Auvil; James R Downing; Mignon L Loh; Cheryl L Willman; Daniela S Gerhard; Charles G Mullighan; Stephen P Hunger; Jinghui Zhang Journal: Nat Commun Date: 2015-03-19 Impact factor: 14.919
Authors: C Mårten Lindqvist; Anders Lundmark; Jessica Nordlund; Eva Freyhult; Diana Ekman; Jonas Carlsson Almlöf; Amanda Raine; Elin Övernäs; Jonas Abrahamsson; Britt-Marie Frost; Dan Grandér; Mats Heyman; Josefine Palle; Erik Forestier; Gudmar Lönnerholm; Eva C Berglund; Ann-Christine Syvänen Journal: Oncotarget Date: 2016-09-27
Authors: Zach A Dixon; Lindsay Nicholson; Martin Zeppetzauer; Elizabeth Matheson; Paul Sinclair; Christine J Harrison; Julie A E Irving Journal: Haematologica Date: 2016-12-15 Impact factor: 9.941
Authors: Julia A Meyer; Jinhua Wang; Laura E Hogan; Jun J Yang; Smita Dandekar; Jay P Patel; Zuojian Tang; Paul Zumbo; Sheng Li; Jiri Zavadil; Ross L Levine; Timothy Cardozo; Stephen P Hunger; Elizabeth A Raetz; William E Evans; Debra J Morrison; Christopher E Mason; William L Carroll Journal: Nat Genet Date: 2013-02-03 Impact factor: 38.330
Authors: K Malinowska-Ozdowy; C Frech; A Schönegger; C Eckert; G Cazzaniga; M Stanulla; U zur Stadt; A Mecklenbräuker; M Schuster; D Kneidinger; A von Stackelberg; F Locatelli; M Schrappe; M A Horstmann; A Attarbaschi; C Bock; G Mann; O A Haas; R Panzer-Grümayer Journal: Leukemia Date: 2015-04-28 Impact factor: 11.528